Anti-Mouse CD8α Antibody (YTS 105.18)
Based on 1 Customer Validation
Anti-Mouse CD8α Antibody (YTS 105.18) is a non-depleting rat IgG2a monoclonal antibody that binds to CD8α on mouse CD8+ T cells. When used in combination with a non-depleting anti-CD4 antibody, Anti-Mouse CD8α Antibody (YTS 105.18) does not deplete CD8+ T cells, but instead promotes the induction of peripheral tolerance in this cell subset. Anti-Mouse CD8α Antibody (YTS 105.18) can be used for research on graft rejection. The recommended isotype control is Mouse IgG2a kappa, Isotype Control (HY-P99978).
For research use only. We do not sell to patients.
- Purity : 99.9%
- Molecular Weight:143.15 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Rat IgG2a kappa
Recommend Isotype Controls
Species Reactivity
Mouse
In Vitro
In Vivo
Anti-Mouse CD8α Antibody (YTS 105.18) (7 mg total per mouse; 1-3 weeks) co-administered with a non-depleting anti-CD4 antibody enables chimerism induction and permanent transplantation tolerance to minor antigen-mismatched B10.BR bone marrow and skin allografts in CBA/Ca mice[1].
Anti-Mouse CD8α Antibody (YTS 105.18) (7 mg total per mouse; three times per week; 3 weeks) co-administered with a non-depleting anti-CD4 antibody modulates CD4 antigen expression in normal CBA/Ca mice without causing significant depletion of CD4+ or CD8+ T cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CBA/Ca mice (age- and sex-matched)[1]
-
Dosage:7 mg total per mouse
-
Administration:every other day; 2 weeks
-
Result:Enabled all treated mice to accept initial B10.BR skin graft for >90 days.
Sustained survival of initial and second B10.BR grafts for >200 days.
Induced immediate rejection of third-party BALB/c skin graft.
Caused no significant depletion of CD4+ T cells at end of treatment.
Resulted in undetectable residual antibody after day 42.
-
Animal Model:CBA/Ca mice (age- and sex-matched)[1]
-
Dosage:7 mg total per mouse
-
Administration:three times per week; 3 weeks
-
Result:Produced minimal reduction in total T cell numbers.
Caused significant modulation of CD4 antigen expression.
Resulted in no depletion of CD8+ cells, as evidenced by total rat IgG2a-coated cells exceeding CD4+ cells alone and a significant Thy-1+CD4-CD8- population in treated mice.
Gene ID
Accession
Target
CD8α
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
ELISA, FACS, Functional assay, Research in vivo
Verified Bioactivity
-
Immobilized CD8 alpha Protein, Mouse (HEK293, HY-P77520) can bind Anti-Mouse CD8α Antibody (YTS 105.18). The ED50 for this effect is 65.8 ng/mL.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 143.15 kDa
-
Color Colorless to light yellow
-
SMILES
[Anti-Mouse CD8α Antibody (YTS 105.18)]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-Mouse CD8α Antibody (YTS 105.18) Related Classifications
HY-P992063 Related Classifications
Powered by Bioz